Explore Dr. Andrew Hill's comprehensive neuroscience insights on egcg. This collection spans articles, podcast conversations, and live neurofeedback sessions, covering the latest research, clinical applications, and practical strategies.

From 25+ years of clinical neuroscience and 25,000+ brain maps, Dr. Hill brings evidence-based approaches to brain optimization, combining rigorous research with accessible explanations designed for intelligent, curious readers seeking to understand and optimize their brains.

Livestreams on EGCG

Live Q&A sessions from Neurofeedback & Chill where Dr. Hill demonstrates protocols, answers viewer questions, and explores egcg applications in real-time with QEEG examples and brain training discussions.

Latest Sessions

🧠 NFB & Chill: Can We "Clean" an Aging Brain? Alzheimer's research on Nicotinamide & EGCG
Livestream

🧠 NFB & Chill: Can We "Clean" an Aging Brain? Alzheimer's research on Nicotinamide & EGCG

👉Book a free consult call: https://calendly.com/drhill1 A new UC Irvine paper reports that nicotinamide (vitamin B3) + EGCG (green tea catechin) restored neuronal GTP and mobilized endocytosis/lysosomal autophagy—clearing intraneuronal Aβ aggregates in aged/AD‑model neurons after just 24 hours in vitro. Today I’ll translate that mechanism (GTP → Rab7/Arl8b vesicle traffic) for humans, then triangulate it with human NAD‑axis data—including NR brain MRS studies and a Phase 2a AD trial of high‑dose nicotinamide—to build a realistic framework for what might (and might not) generalize from dish/mouse to people Key human anchors we’ll use: • NR raises brain NAD in humans: ^31P‑MRS in Parkinson’s (NADPARK, 1 g/day, 30 days) and downfield ^1H‑MRS in healthy volunteers (single 900 mg dose).  • High‑dose nicotinamide in early AD (NEAT): safe, no significant CSF p‑Tau231 reduction at 48 weeks (3 g/day); PK/PD shows heavy methylation to MeNAM and CSF NAM quantifiable in only ~32%—a big translational clue.   • Older adults crossover trial: oral NR (1 g/day for 6 weeks) increased NAD in neuron‑enriched extracellular vesicles and reduced NEV Aβ42—biomarkers plausibly linked to brain processes.  • BBB & transport: Equilibrative nucleoside transporters (ENTs) at the brain endothelium are a plausible entry route for ribosides; ENT2 has been functionally implicated in BBB transport.  • EGCG safety: EFSA’s 2018 evaluation and the UK COT (2024) update caution about hepatotoxicity at high supplemental doses, with ≤800 mg/day EGCG generally considered the upper bound without signal in supervised settings.   Key takeaways (for sophisticated viewers) • Mechanism: The UCI work spotlights neuronal GTP availability as a rate‑limiter for vesicle trafficking/autophagy; NAM + EGCG rescued GTP and “clearing” pathways in vitro—a different lever than classic ATP narratives.  • Translation hinge: In humans, raising brain NAD is feasible (NR studies), but turning that into sustained neuronal mtGTP and higher Rab7/Arl8b traffic is unproven; any effect likely depends on exposure profile at the BBB and in neurons, not just total daily dose.  • NAM vs. NR: NEAT shows safe 3 g/day NAM but no primary biomarker win and significant methylation to MeNAM with low/variable CSF NAM—suggesting delivery & metabolism, not target biology per se, may be the bottleneck.   • Safety reality: For EGCG, tea intake is different from high‑dose extracts; regulatory reviews keep ≤800 mg/day EGCG as a practical ceiling for supplemental use, with idiosyncratic hepatotoxicity risk above that. This video is not medical advice.   REFERENCES (live links) UCI press release on GeroScience paper (Aug 6, 2025): https://news.uci.edu/2025/08/06/uc-irvine-researchers-find-combination-of-natural-compounds-for-brain-cleaning/ Santana et al., GeroScience (2025) – NAM + EGCG restore neuronal GTP & autophagy: https://pubmed.ncbi.nlm.nih.gov/40751793/ https://link.springer.com/article/10.1007/s11357-025-01786-4 Grill et al., NEAT Phase 2a (Neurology, 2025) – Nicotinamide 3 g/day in early AD: https://pubmed.ncbi.nlm.nih.gov/39671543/ Ketron et al., PK/PD from NEAT (Alzheimer’s Research & Therapy, 2025) – CSF NAM & MeNAM: https://pmc.ncbi.nlm.nih.gov/articles/PMC11895359/ Brakedal et al., NADPARK (Cell Metabolism, 2022) – NR raises brain NAD by 31P‑MRS: https://pubmed.ncbi.nlm.nih.gov/35235774/ Nanga et al., MRM (2024) – Acute 900 mg NR raises human brain NAD by DF‑1H MRS: https://pubmed.ncbi.nlm.nih.gov/39044608/ Vreones et al., Aging Cell (2023) – NR in older adults: ↑NEV NAD, ↓NEV Aβ42: https://pmc.ncbi.nlm.nih.gov/articles/PMC9835564/ Rab7/Arl8b in late endosome–lysosome traffic: https://pmc.ncbi.nlm.nih.gov/articles/PMC5040976/ https://www.nature.com/articles/s41467-024-44957-1 TCA cycle GTP step (SCS): https://www.jbc.org/article/S0021-9258(22)01281-9/fulltext ENT2 and BBB transport: https://pmc.ncbi.nlm.nih.gov/articles/PMC8410084/ EGCG safety – EFSA opinion (2018) & UK COT statement (2024): https://pmc.ncbi.nlm.nih.gov/articles/PMC7009618/ https://cot.food.gov.uk/sites/default/files/2024-11/COT%2008.2024%20-%20Statement%20on%20the%20hepatotoxicity%20of%20green%20tea%20catechins_Lay%20summary_FINAL%20%28003%29.pdf -- Note: Educational only. Not medical advice. If this is helpful, please like, subscribe, and share. Questions? Drop them in the comments—I read them all. ⏰ Live 6 PM Pacific Mondays Subscribe and hit the bell for weekly brain health updates! 🧠 RESOURCES 🧠 👉Book a free consult call: https://calendly.com/drhill1 👉$250 off QEEG Brain Mapping at Peak Brain: https://peakbraininstitute.com/special/ 💡Whether you're a biohacking enthusiast, longevity seeker, or just curious about optimizing your health, this episode packs actionable insights backed by the latest research . #NAD #Nicotinamide #NR #EGCG #Alzheimers #Parkinsons #Autophagy #MRS #BrainHealth #Neuroscience